Celgene International Sárl (CELG) Oral Anti-Cancer Therapy REVLIMID® (lenalidomide) Now Indicated as a Treatment for Patients With Rare Form of Blood Disease
6/17/2013 9:33:05 AM
More...
|
Celgene International Sárl (CELG)'s Apremilast Improves Oral Ulcer Pain From Behcet's Disease
6/14/2013 7:16:59 AM
More...
|
Celgene International Sárl (CELG) Release: Data From Phase III Randomized Controlled Study (Palace 3) of Apremilast in Psoriatic Arthritis Presented at EULAR
6/13/2013 8:44:12 AM
More...
|
Celgene International Sárl (CELG) Release: Signs and Symptoms of Psoriatic Arthritis Significantly Improved in Patients Receiving Long-Term Oral Apremilast Treatment in Phase III Study (PALACE-1)
6/12/2013 9:47:37 AM
More...
|
Celgene International Sárl (CELG) Release: Updated Studies Evaluating POMALYST® (pomalidomide) In Previously Treated Multiple Myeloma Patients Presented at American Society of Clinical Oncology
6/3/2013 12:37:35 PM
More...
|
Celgene International Sárl (CELG) Release: Analyses of MPACT Trial Evaluating ABRAXANE® Combination Therapy for the Treatment of Advanced Pancreatic Cancer Presented at American Society of Clinical Oncology 2013
6/3/2013 10:51:09 AM
More...
|
Celgene International Sárl (CELG) Release: Study Evaluating REVLIMID® Combination Compared to Autologous Stem Cell Transplant with or without REVLIMID Maintenance in Newly-Diagnosed Multiple Myeloma Presented at American Society of Clinical Oncology
6/3/2013 7:59:00 AM
More...
|
Oral Anti-Cancer Therapy Pomalidomide Celgene International Sárl (CELG) Receives Positive CHMP Opinion as Treatment for Patients With Relapsed and Refractory Multiple Myeloma
5/31/2013 1:14:05 PM
More...
|
Celgene International Sárl (CELG) Announces U.S. FDA Grants Priority Review for ABRAXANE® sNDA in Advanced Pancreatic Cancer
5/23/2013 11:08:54 AM
More...
|
Celgene International Sárl (CELG) Release: Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials
1/7/2013 10:24:21 AM
More...
|
|